Navigation Links
Xeomin® (incobotulinumtoxinA) Data To Be Presented At The 71st Annual Assembly Of The American Academy Of Physical Medicine And Rehabilitation
Date:11/5/2010

gical disorders as well as for aesthetic medicine. Global research is concentrated in fields that have a strong need for therapeutic innovation such as Alzheimer's disease, Parkinson's disease, tinnitus, chronic pain conditions, addictions, and neuromuscular disturbances.

XEOMIN is a registered trademark of MerzPharma GmbH & Co KGaA.  Botox is a registered trademark of Allergan, Inc.


'/>"/>
SOURCE Merz Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Xeomin® (incobotulinumtoxinA) - a Botulinum Toxin Free From Accessory Proteins - Now Available in the U.S.
2. FDA Approves Merz Pharmaceuticals Xeomin® (incobotulinumtoxinA) for the Treatment of Cervical Dystonia and Blepharospasm
3. Romark Announces Data Presented at AASLD Meeting 2010
4. Medivir Notes That Partner Tibotec Announced Week 24 Interim Results From Phase 2b TMC435 PILLAR Study to be Presented as a Late-Breaker at AASLD
5. ANA598 Data Presented at AASLD Highlight Positive Clinical Profile of DAA Entering Phase IIb
6. Over 20 New Clinical Studies Presented on Masimo Noninvasive Patient Monitoring Technologies at the American Society of Anesthesiologists Annual Meeting
7. New Analysis of CAMBIA™ Pivotal Data to be Presented at the 4th World Congress on Controversies in Neurology
8. Positive Results From LigoCytes Norovirus Vaccine Challenge Study Presented at IDSA Annual Meeting
9. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
10. Celsion Announces ThermoDoxs Prominence in Abstracts Presented at the 2nd International MR-Guided Ultrasound Symposium
11. New FORTEO® and EVISTA® Data to be Presented at Premiere Scientific Meeting for Bone and Mineral Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... Lumin Medical LLC, a healthcare IT provider, ... leading provider of on-demand patient tracking solutions and is ... to Franklin, Wis. ... and our mission is to provide visibility for the ... reduce costs," said James Hermann , President of ...
(Date:7/14/2014)... DIEGO , July 14, 2014  More than any ... their smartphones and tablet computers -- but their eyes don,t. ... have never needed before, and the eye has not evolved ... and what our eyes can do comfortably often results in ... collectively known as Digital Eye Strain. Now ZEISS has invented ...
(Date:7/14/2014)... EAGAN, Minn. , July 14, 2014  Today, ... Partners, announced that it acquired the assets of MicroTest ... MA.  The acquisition of MTL is the first step ... and chemistry laboratory services platform to support the medical ... be known as Accuratus Lab Services , a ...
Breaking Medicine Technology:Lumin Medical Purchases PatientTrak 2Lumin Medical Purchases PatientTrak 3New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 2New Eyeglass Lens Helps Our Eyes Keep Up with our Digital Lives 3ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 2ATS Labs, Inc. Announces the Acquisition of MicroTest Labs, Inc. 3
... III Study for the Treatment of Advanced Prostate CancerPARSIPPANY, ... launch of a Phase IIIB clinical trial of degarelix ... antagonist approved by the U.S. Food and Drug Administration ... cancer. The announcement was made at ...
... Diagnostic ToolSUNNYVALE, Calif., April 27 Cepheid (Nasdaq: ... MTB/RIF as a CE IVD Mark product under the ... Devices. For the first time, European clinicians will have ... Mycobacterium tuberculosis (MTB) and resistance to rifampicin ...
Cached Medicine Technology:Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 2Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 3Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 4Ferring Pharmaceuticals Launches Phase IIIB Trial of Degarelix as Intermittent Therapy 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 2Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 3Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 4Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 5Cepheid Announces European Release of First On-Demand Molecular Test for Simultaneous Detection of Mycobacterium tuberculosis (TB) and Resistance to Rifampicin 6
(Date:7/14/2014)... entered into an agreement with one of the ... drug candidates for the detection and treatment of ... novel antibody discovery and Roche,s expertise in developing ... possibility of improved treatment for cancer, a leading ... makes use of BTI,s discovery of a new ...
(Date:7/14/2014)... Florida (PRWEB) July 14, 2014 Botanica ... Open House event will be held at the day ... July 16th from 4-8pm. Wine and other refreshments will ... of retail discounts on beauty products and ... treatment known as dermaplaning. , Dermaplaning (also known ...
(Date:7/14/2014)... Barbara Bronson Gray ... (HealthDay News) -- New research suggests that a faltering ... Alzheimer,s disease, and that an inexpensive, low-tech smell test ... In two different studies, the decreased ability to ... cell function and progression to Alzheimer,s disease. "We,re ...
(Date:7/14/2014)... HealthDay Reporter MONDAY, July 14, 2014 (HealthDay ... have bigger brains and sharper thinking skills than their peers, ... between playing games such as puzzles, crosswords, cards and checkers ... Researchers found that people who played those games at ... and other mental functions. And, based on MRI scans, they ...
(Date:7/14/2014)... Atlanta, GA (PRWEB) July 14, 2014 ... networking and relationship-marketing firm, announced today that nominations ... for the 2014 Information Security Executive® (ISE®) North ... Security Executive® of the Year, which recognizes executives ... organizations through risk management, data-asset protection, regulatory compliance, ...
Breaking Medicine News(10 mins):Health News:A*STAR partners Roche to develop new cancer therapeutics 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 2Health News:Botanica Day Spa to Feature Dermaplaning at Upcoming Open House 3Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 2Health News:Could a Simple Smell Test Help Spot Alzheimer's Early? 3Health News:Can Games, Puzzles Keep Aging Minds Sharp? 2Health News:Can Games, Puzzles Keep Aging Minds Sharp? 3Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 2Health News:T.E.N. Accepting Nominations for the 2014 Information Security Executive® North America Awards 3
... liver disease (NAFLD) is the most common cause of ... for patients with NAFLD is currently available//. Understanding the ... patients with NAFLD is important for patient counseling as ... ,To deal with these issues, researchers from Mayo Clinic ...
... genetically modified mosquito has been created that wipe out natural ... of the world such as India and South Asia. ... the wild in an attempt to combat malaria that is ... ,A similar attempt was made in India in 1970s ...
... to start its Phase III cancer vaccine trial against ... is the new skin cancer vaccine developed by Antigenics.// ... 322 patients failed to meet the required statistically significance ... was not shown to have any better results compared ...
... news for adults with acne and resultant facial scarring. ... Surgery, the medical journal of the American Society for ... - or non-ablative - lasers showed significant improvement of ... common with ablative procedures, such as facial resurfacing, dermabrasion ...
... survival rate of women with breast cancer has increased by ... years//. The experts feel that the increase in breast cancer ... detection of breast cancer and also due to more effective ... of cancer. ,Professor Michel Coleman, Epidemiologist, Cancer Research ...
... found that it is better to insert drug-coated stents ... who have diabetes//. ,The study author Dr. ... University Hospital in Madrid said that the results of ... have poorer prognosis as compared to non-diabetics after angioplasty. ...
Cached Medicine News:Health News:Weight reduction by 5% may help in treating nonalcoholic fatty liver disease 2Health News:Breast cancer women has shown an increase in survival rates 2
... a low osmolar ionic dimer. Each ... meglumine, 196 mg of ioxaglate sodium ... disodium as a stabilizer. The solution ... each milliliter and provides 32% (320 ...
... IMAGOPAQUE is a non-ionic monomeric contrast ... in adults and children. After a decade ... 3.5 million examinations, IMAGOPAQUE has proven to ... effort in hundreds of radiology departments.Results from ...
... is a liver-specific contrast agent approved for ... Its introduction expands the Amersham Health portfolio ... injected intravenously, TESLASCAN aids in the detection, ... Imaging can begin within minutes of injection, ...
... a new Contrast Agent for ... of stabilized SF6 microbubbles. The ... between 1 and 10 m, ... 2 and 5 x 108 ...
Medicine Products: